$121.03
4.213.6%
Last update: Oct 15, 2:31 PM
$118.50
1.681.44%
Halozyme Therapeutics Inc
HALONASDAQ
Halozyme Therapeutics (HALO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Halozyme Therapeutics (HALO) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided earnings per share in the range of $8.65 - $9, compared to a consensus EPS estimate of $8.02. Halozyme Therapeutics also guided revenue in the range of $1.83B - $1.91B for the period.
Compared to prior guidance, Halozyme Therapeutics raised its EPS outlook from a previous range of $7.75 - $8.25. On the revenue side, the company raised its revenue forecast from a prior range of $1.71B - $1.81B.
Halozyme Therapeutics has issued 25 guidance updates between November 8, 2022 and August 6, 2026. During this period, the company raised its outlook 14 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.80 | $1.51 | $2.15 | $1.58 |
| Actual | $2.28 | $1.60 | $-0.24 | $1.72 |
| Surprise | +26.7% | +5.96% | -111.2% | +8.86% |
| Revenue | ||||
| Estimate | $405.2M | $358.8M | $447.1M | $338.3M |
| Actual | $481.0M | $376.7M | $451.8M | $354.3M |
| Surprise | +18.7% | +4.99% | +1.04% | +4.72% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.29 | $2.60 | $1.98 | $2.35 |
| Revenue | ||||
| Consensus | $488.1M | $543.9M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $2.28 | $1.80 | 26.7 % |
| Q1 | May 11, 2026 | $1.60 | $1.51 | 5.96 % |
| Q4 | Feb 17, 2026 | $-0.24 | $2.15 | -111.2 % |
| Q3 | Nov 3, 2025 | $1.72 | $1.58 | 8.86 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $481.00M | $405.15M | 18.7 % |
| Q1 | May 11, 2026 | $376.71M | $358.79M | 4.99 % |
| Q4 | Feb 17, 2026 | $451.77M | $447.13M | 1.04 % |
| Q3 | Nov 3, 2025 | $354.26M | $338.29M | 4.72 % |
